There has never been a way to diagnose Alzheimer’s disease in living people — until now. The U.S. Food and Drug Administration last week gave pre-approval to a new screening for early detection of Alzheimer’s that can reveal the unique plaques that characterize the disease years before it manifests.
The New York Times reports officials believe the tests will be widely available before the end of the year. What does this mean?
It’s a major breakthrough in neurology that raises huge ethical and personal implications in the management of this life-altering disease.
Would you want to know? Is your doctor obligated to tell you? What are the implications?
In the latest episode of RealCareNowTV, Dr. Bill Thomas is joined by geriatrician and dementia expert Dr. Al Power, author of Dementia Beyond Drugs, to discuss this difficult question.
